Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick A Ott

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
Nature Reviews. Clinical Oncology|March 14, 2018
Immunotherapy: Immune-modified response criteria - an iterative learning process?Patrick A Ott
Annals of Translational Medicine|December 24, 2015
Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapyPatrick A Ott
Nature Biotechnology|March 11, 2026
The promises and challenges of neoantigen cancer vaccinesPatrick A Ott
Hematology/Oncology Clinics of North America|March 6, 2019
Immunotherapy: An Old and New Modality for the Treatment of CancerPatrick A Ott
Cancer Cell|November 9, 2021
Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effectPatrick A Ott
Hematology/Oncology Clinics of North America|March 6, 2019
Intralesional Cancer ImmunotherapiesPatrick A Ott
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2022
PD-1 Inhibition-Trouble for Subsequent TIL Therapy in Patients with Melanoma?Eryn Blass, Patrick A Ott
Frontiers in Immunology|November 7, 2013
Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell FunctionPatrick A Ott, Nina Bhardwaj
Nature Reviews. Clinical Oncology|January 21, 2021
Advances in the development of personalized neoantigen-based therapeutic cancer vaccinesEryn Blass, Patrick A Ott
Immunotherapy|February 17, 2011
Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatmentPatrick A Ott, Sylvia Adams
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
Nature Reviews. Clinical Oncology|March 14, 2018
Immunotherapy: Immune-modified response criteria - an iterative learning process?Patrick A Ott
Annals of Translational Medicine|December 24, 2015
Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapyPatrick A Ott
Nature Biotechnology|March 11, 2026
The promises and challenges of neoantigen cancer vaccinesPatrick A Ott
Hematology/Oncology Clinics of North America|March 6, 2019
Immunotherapy: An Old and New Modality for the Treatment of CancerPatrick A Ott
Cancer Cell|November 9, 2021
Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effectPatrick A Ott
Hematology/Oncology Clinics of North America|March 6, 2019
Intralesional Cancer ImmunotherapiesPatrick A Ott
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2022
PD-1 Inhibition-Trouble for Subsequent TIL Therapy in Patients with Melanoma?Eryn Blass, Patrick A Ott
Frontiers in Immunology|November 7, 2013
Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell FunctionPatrick A Ott, Nina Bhardwaj
Nature Reviews. Clinical Oncology|January 21, 2021
Advances in the development of personalized neoantigen-based therapeutic cancer vaccinesEryn Blass, Patrick A Ott
Immunotherapy|February 17, 2011
Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatmentPatrick A Ott, Sylvia Adams
Pageof 18